A Study of Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy
Status:
Completed
Trial end date:
2018-10-02
Target enrollment:
Participant gender:
Summary
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The
blinded phase only will be described in this record. Participants will be randomized in a 4:1
ratio to receive GWP42003-P or matching placebo. The hypothesis is that levels of stiripentol
(STP) or valproate (VPA) may be altered (increased or decreased) as a result of using
GWP42003-P.